¼¼°èÀÇ ÆÐÇ÷Áõ Áø´Ü ½ÃÀå º¸°í¼­(2025³â)
Sepsis Diagnostics Global Market Report 2025
»óǰÄÚµå : 1751112
¸®¼­Ä¡»ç : The Business Research Company
¹ßÇàÀÏ : On Demand Report
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 175 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,490 £Ü 6,138,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,490 £Ü 8,872,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,490 £Ü 11,606,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

ÆÐÇ÷Áõ Áø´Ü ½ÃÀå ±Ô¸ð´Â ÇâÈÄ ¸î ³â µ¿¾È °­·ÂÇÑ ¼ºÀå¼¼¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2029³â±îÁö ¿¬Æò±Õ 8.2%ÀÇ CAGR·Î 14¾ï 7,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹Ãø ±â°£ µ¿¾ÈÀÇ ¼ºÀåÀº ½Å¼ÓÇÑ Áø´Ü¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, ÀÇ·á ÀÎÇÁ¶ó¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡, ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ °ü½É Áõ°¡, Ç×±ÕÁ¦ ³»¼º Áõ°¡, Â÷¼¼´ë ½ÃÄö½ÌÀÇ »ç¿ë Áõ°¡¿¡ ±âÀÎÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹Ãø ±â°£ µ¿¾È ¿¹»óµÇ´Â ÁÖ¿ä µ¿ÇâÀ¸·Î´Â Áø´Ü¿¡ AIÀÇ ÅëÇÕ, ¹ÙÀÌ¿À¸¶Ä¿ÀÇ ±â¼ú ¹ßÀü, ºÐÀÚÁø´ÜÀÇ ¹ßÀü, ÀÚµ¿È­ ¹× µðÁöÅÐ Áø´Ü Ç÷§ÆûÀ¸·ÎÀÇ Àüȯ, Áø´Ü¿¡ ÀÖ¾î ÀΰøÁö´ÉÀÇ Áö¼ÓÀûÀÎ ¹ßÀü µîÀÌ ÀÖ½À´Ï´Ù.

º´¿ø³» °¨¿°(HAI)ÀÇ Áõ°¡´Â ÆÐÇ÷Áõ Áø´ÜÁ¦ ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, HAI´Â ȯÀÚ°¡ ÀÇ·á±â°ü¿¡ ÀÔ¿ø Áß ¶Ç´Â ÀÔ¿ø ÈÄ ¹ß»ýÇÏ´Â °¨¿°À¸·Î, ÀϹÝÀûÀ¸·Î ÀÔ¿ø ÈÄ 48½Ã°£ ÀÌ»ó °æ°úÇÑ ÈÄ ¹ßº´Çϸç, ÀÔ¿ø ´ç½Ã¿¡´Â ¹ßº´ÇÏÁö ¾Ê¾Ò´ø °¨¿°À» ¸»ÇÕ´Ï´Ù. Ç×»ýÁ¦ ³»¼º ¹®Á¦°¡ Ä¿Áö°í ÀÖ´Â °ÍÀÌ ÁÖ¿ä ¿øÀÎÀÔ´Ï´Ù. ÀÇ·áÇöÀå¿¡¼­ÀÇ Ç×»ýÁ¦ ³²¿ë°ú ¿À³²¿ëÀÌ ³»¼º±ÕÀÇ ¹ß»ýÀ» ÃÊ·¡ÇÏ¿© °¨¿°ÁõÀÇ Ä¡·á¸¦ ¾î·Æ°Ô ¸¸µé°í ÀÖ½À´Ï´Ù. ÆÐÇ÷Áõ Áø´ÜÀº º´¿ø³» °¨¿°À» Á¶±â¿¡ ¹ß°ßÇÏ¿© Àû½Ã¿¡ Ä¡·áÇϰí ÇÕº´ÁõÀ» ÁÙÀÏ ¼ö ÀÖ´Â º´¿øÃ¼ ¹× ¹ÙÀÌ¿À¸¶Ä¿¸¦ ½Äº°ÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2024³â 11¿ù È£ÁÖº¸°Çº¹Áö¿¬±¸¿ø(Australian Institute of Health and Welfare)Àº 2022-2023³â ÀÇ·á°ü·Ã°¨¿°(HAC)ÀÌ °ø¸³º´¿ø ÀÔ¿øÀÇ 2%, »ç¸³º´¿ø ÀÔ¿øÀÇ 0.8%¿¡¼­ ¹ß»ýÇßÀ¸¸ç, HAI°¡ °¡Àå ºó¹øÇÑ ÇÕº´ÁõÀ¸·Î ³ªÅ¸³µ´Ù°í º¸°íÇß½À´Ï´Ù. °¡Àå ºó¹øÇÑ ÇÕº´ÁõÀ¸·Î º¸°íÇÏ¿´½À´Ï´Ù. ±× °á°ú, º´¿ø³» °¨¿° ¹ß»ý·üÀÇ Áõ°¡°¡ ÆÐÇ÷Áõ Áø´ÜÁ¦ ½ÃÀåÀ» Å©°Ô °ßÀÎÇϰí ÀÖ½À´Ï´Ù.

ÆÐÇ÷Áõ Áø´Ü ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷µéÀº ±âÁ¸ÀÇ Ç÷¾× ¹è¾ç¿¡ ÀÇÁ¸ÇÏÁö ¾Ê°í ÆÐÇ÷ÁõÀ» ½Å¼ÓÇϰí Á¤È®ÇÏ°Ô °ËÃâÇÒ ¼ö ÀÖ´Â ¹«¹è¾ç Áø´Ü ½Ã½ºÅÛ°ú °°Àº Çõ½ÅÀûÀÎ ¼Ö·ç¼Ç °³¹ß¿¡ ÁÖ·ÂÇϰí ÀÖ½À´Ï´Ù. ¹«¹è¾ç Áø´Ü ½Ã½ºÅÛÀº ÁßÇÕÈ¿¼Ò ¿¬¼â ¹ÝÀÀ(PCR), Â÷¼¼´ë¿°±â¼­¿­ºÐ¼®(NGS), ¸é¿ªºÐ¼® µî ÷´Ü ±â¼úÀ» Ȱ¿ëÇÏ¿© Ç÷¾×, Ÿ¾×, Á¶Á÷ µî ȯÀÚ »ùÇÿ¡¼­ Á÷Á¢ º´¿ø±ÕÀ» È®ÀÎÇÕ´Ï´Ù. ¿¹¸¦ µé¾î, 2024³â 4¿ù ½ºÆäÀο¡ º»»ç¸¦ µÐ Deepull Diagnostics S.L.»ç°¡ ÆÐÇ÷Áõ Á¶±â ¹ß°ßÀ» À§ÇÑ UllCORE Áø´Ü ½Ã½ºÅÛÀ» Ãâ½ÃÇß½À´Ï´Ù. ÀÌ ¹è¾ç ÇÊ¿ä ¾ø´Â ¸ÖƼÇ÷º½º PCR Ç÷§ÆûÀº ÆÐÇ÷Áõ ¹× ±âŸ ±Þ¼º °¨¿°¼º Áúȯ¿¡¼­ º´¿ø±ÕÀ» ½Å¼ÓÇÏ°Ô ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ½Ã½ºÅÛÀº 8mLÀÇ ÀüÇ÷¿¡¼­ ¹Ì»ý¹° DNA¸¦ ÃßÃâÇÏ¿© ´Ü 1½Ã°£ ¸¸¿¡ 50°³ÀÇ º¸°í °¡´ÉÇÑ °á°ú¸¦ Á¦°øÇÕ´Ï´Ù. ÀÌ ½Ã½ºÅÛÀº ¹ÚÅ׸®¾Æ, °õÆÎÀÌ, Ç×»ýÁ¦ ³»¼º À¯ÀüÀÚ¸¦ Æ÷ÇÔÇÑ ÆÐÇ÷ÁõÀ» À¯¹ßÇÏ´Â º´¿ø±ÕÀÇ 95%¸¦ °ËÃâÇÏ¿© Á¶±â Áø´ÜÀ» °³¼±Çϰí Ç×»ýÁ¦ ¿À³²¿ëÀ» ÁÙÀÌ´Â µ¿½Ã¿¡ º´¿øÀÌ Ç×±ÕÁ¦ ³»¼ºÀ» ÅðÄ¡ÇÒ ¼ö ÀÖµµ·Ï µ½½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå Æ¯Â¡

Á¦3Àå ½ÃÀå µ¿Çâ°ú Àü·«

Á¦4Àå ½ÃÀå - ±Ý¸®, ÀÎÇ÷¹À̼Ç, ÁöÁ¤ÇÐ, ¹«¿ª ÀüÀï°ú °ü¼¼, ±×¸®°í Äڷγª¿Í ȸº¹ÀÌ ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» Æ÷ÇÔÇÑ °Å½Ã°æÁ¦ ½Ã³ª¸®¿À

Á¦5Àå ¼¼°èÀÇ ¼ºÀå ºÐ¼®°ú Àü·« ºÐ¼® ÇÁ·¹ÀÓ¿öÅ©

Á¦6Àå ½ÃÀå ¼¼ºÐÈ­

Á¦7Àå Áö¿ªº°¡¤±¹°¡º° ºÐ¼®

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå

Á¦9Àå Áß±¹ ½ÃÀå

Á¦10Àå Àεµ ½ÃÀå

Á¦11Àå ÀϺ» ½ÃÀå

Á¦12Àå È£ÁÖ ½ÃÀå

Á¦13Àå Àεµ³×½Ã¾Æ ½ÃÀå

Á¦14Àå Çѱ¹ ½ÃÀå

Á¦15Àå ¼­À¯·´ ½ÃÀå

Á¦16Àå ¿µ±¹ ½ÃÀå

Á¦17Àå µ¶ÀÏ ½ÃÀå

Á¦18Àå ÇÁ¶û½º ½ÃÀå

Á¦19Àå ÀÌÅ»¸®¾Æ ½ÃÀå

Á¦20Àå ½ºÆäÀÎ ½ÃÀå

Á¦21Àå µ¿À¯·´ ½ÃÀå

Á¦22Àå ·¯½Ã¾Æ ½ÃÀå

Á¦23Àå ºÏ¹Ì ½ÃÀå

Á¦24Àå ¹Ì±¹ ½ÃÀå

Á¦25Àå ij³ª´Ù ½ÃÀå

Á¦26Àå ³²¹Ì ½ÃÀå

Á¦27Àå ºê¶óÁú ½ÃÀå

Á¦28Àå Áßµ¿ ½ÃÀå

Á¦29Àå ¾ÆÇÁ¸®Ä« ½ÃÀå

Á¦30Àå °æÀï ±¸µµ¿Í ±â¾÷ °³¿ä

Á¦31Àå ±âŸ ÁÖ¿ä ±â¾÷°ú Çõ½ÅÀû ±â¾÷

Á¦32Àå ¼¼°èÀÇ ½ÃÀå °æÀï º¥Ä¡¸¶Å·°ú ´ë½Ãº¸µå

Á¦33Àå ÁÖ¿ä ÀμöÇÕº´

Á¦34Àå ÃÖ±ÙÀÇ ½ÃÀå µ¿Çâ

Á¦35Àå ½ÃÀå ÀáÀç·ÂÀÌ ³ôÀº ±¹°¡, ºÎ¹®, Àü·«

Á¦36Àå ºÎ·Ï

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Sepsis diagnostics refers to a range of advanced technologies and tests designed to quickly detect the presence of sepsis, a critical condition that can lead to organ failure and death if not treated promptly. These diagnostic tools enable healthcare providers to assess the severity of sepsis and make timely, informed decisions to initiate appropriate treatments, ultimately improving patient survival rates.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The main products in sepsis diagnostics include instruments, blood culture media, assay kits and reagents, and software. Instruments are medical devices used to rapidly analyze blood samples and detect pathogens, allowing for the early and accurate identification of sepsis and facilitating timely treatment. Sepsis diagnostics employ various technologies such as microbiology, molecular diagnostics, immunoassays, and flow cytometry to detect different types of pathogens, including bacterial, fungal, viral sepsis, and others. The diagnostic methods include both automated and conventional diagnostic approaches. These tools are used by various end-users, including hospitals and clinics, pathology and reference laboratories, and research institutes.

The sepsis diagnostics market research report is one of a series of new reports from The Business Research Company that provides sepsis diagnostics market statistics, including the sepsis diagnostics industry global market size, regional shares, competitors with the sepsis diagnostics market share, detailed sepsis diagnostics market segments, market trends, and opportunities, and any further data you may need to thrive in the sepsis diagnostics industry. This sepsis diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The sepsis diagnostics market size has grown strongly in recent years. It will grow from $0.99 billion in 2024 to $1.07 billion in 2025 at a compound annual growth rate (CAGR) of 8.3%. The growth during the historic period can be attributed to the increasing incidence of sepsis, growing awareness about the importance of early diagnosis, rising healthcare expenditure, a growing prevalence of hospital-acquired infections, and the increasing adoption of point-of-care testing.

The sepsis diagnostics market size is expected to see strong growth in the next few years. It will grow to $1.47 billion in 2029 at a compound annual growth rate (CAGR) of 8.2%. The growth during the forecast period can be attributed to the rising demand for rapid diagnostics, increasing investments in healthcare infrastructure, a growing focus on personalized medicine, the increasing prevalence of antimicrobial resistance, and the rising use of next-generation sequencing. Key trends expected in the forecast period include the integration of AI in diagnostics, technological advancements in biomarkers, progress in molecular diagnostics, a shift toward automated and digital diagnostic platforms, and the continued advancement of artificial intelligence in diagnostics.

The rising incidence of hospital-acquired infections (HAIs) is expected to drive growth in the sepsis diagnostics market. HAIs are infections that develop during or after a patient's stay in a healthcare facility, typically 48 hours or more after admission, and were not present at the time of admission. The increase in HAIs is largely due to the growing issue of antibiotic resistance. Overuse and misuse of antibiotics in healthcare settings have led to the development of resistant bacteria, making infections more difficult to treat. Sepsis diagnostics play a critical role by enabling early detection of hospital-acquired infections, identifying pathogens and biomarkers that allow for timely treatment and reduced complications. For instance, in November 2024, the Australian Institute of Health and Welfare reported that in 2022-2023, healthcare-associated infections (HACs) occurred in 2% of public hospital admissions and 0.8% of private hospital admissions, with HAIs being the most frequent complication. As a result, the rising incidence of hospital-acquired infections is significantly driving the sepsis diagnostics market.

Key players in the sepsis diagnostics market are focusing on the development of innovative solutions, such as culture-free diagnostic systems, to enable rapid and accurate detection of sepsis without relying on traditional blood cultures. Culture-free diagnostics leverage advanced technologies, including polymerase chain reaction (PCR), next-generation sequencing (NGS), or immunoassays, to identify pathogens directly from patient samples such as blood, saliva, or tissue. For example, in April 2024, Deepull Diagnostics S.L., a Spain-based company, launched the UllCORE diagnostic system for early sepsis detection. This culture-free, multiplex PCR platform provides rapid pathogen identification in sepsis and other acute infections. The system extracts microbial DNA from 8 mL of whole blood, offering 50 reportable results in just one hour. It detects 95% of sepsis-causing pathogens, including bacteria, fungi, and antibiotic resistance genes, helping hospitals combat antimicrobial resistance while improving early diagnosis and reducing antibiotic misuse.

In October 2024, Trinity Biotech plc, an Ireland-based medical laboratory company, acquired a 12.5% stake in Novus Diagnostics Ltd. for $2.5 million. This acquisition aims to accelerate the development and commercialization of Novus Diagnostics' rapid point-of-care diagnostic solutions, particularly its 15-minute bloodstream infection test. This rapid test is expected to significantly enhance sepsis diagnosis and improve patient outcomes by enabling faster and more accurate testing for bloodstream infections. Novus Diagnostics is an Ireland-based medical technology company developing diagnostic solutions for sepsis and other bloodstream infections.

Major players in the sepsis diagnostics market are Siemens Healthcare GmbH, F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Becton, Dickinson and Company, Koninklijke Philips N.V., GE Healthcare, Wolters Kluwer N.V., bioMerieux S.A., Bruker Corporation, DiaSorin S.p.A., Cepheid Inc., Seegene Inc., Luminex Corporation, T2 Biosystems Inc., Cytovale Inc., Accelerate Diagnostics Inc., Immunexpress Inc., Sepsis Alliance.

North America was the largest region in the sepsis diagnostics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in sepsis diagnostics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the sepsis diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The sepsis diagnostics market consists of revenues earned by entities by providing services such as clinical consultation, rapid diagnostic testing solutions, point-of-care diagnostic solutions, biomarker testing, and molecular diagnostic testing. The market value includes the value of related goods sold by the service provider or included within the service offering. The sepsis diagnostics market also includes sales of sepsis diagnostic test kits, automated blood culture systems, molecular diagnostic equipment, sepsis biomarker assay kits, and rapid diagnostic devices for infection detection. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Sepsis Diagnostics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on sepsis diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for sepsis diagnostics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The sepsis diagnostics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Sepsis Diagnostics Market Characteristics

3. Sepsis Diagnostics Market Trends And Strategies

4. Sepsis Diagnostics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Sepsis Diagnostics Growth Analysis And Strategic Analysis Framework

6. Sepsis Diagnostics Market Segmentation

7. Sepsis Diagnostics Market Regional And Country Analysis

8. Asia-Pacific Sepsis Diagnostics Market

9. China Sepsis Diagnostics Market

10. India Sepsis Diagnostics Market

11. Japan Sepsis Diagnostics Market

12. Australia Sepsis Diagnostics Market

13. Indonesia Sepsis Diagnostics Market

14. South Korea Sepsis Diagnostics Market

15. Western Europe Sepsis Diagnostics Market

16. UK Sepsis Diagnostics Market

17. Germany Sepsis Diagnostics Market

18. France Sepsis Diagnostics Market

19. Italy Sepsis Diagnostics Market

20. Spain Sepsis Diagnostics Market

21. Eastern Europe Sepsis Diagnostics Market

22. Russia Sepsis Diagnostics Market

23. North America Sepsis Diagnostics Market

24. USA Sepsis Diagnostics Market

25. Canada Sepsis Diagnostics Market

26. South America Sepsis Diagnostics Market

27. Brazil Sepsis Diagnostics Market

28. Middle East Sepsis Diagnostics Market

29. Africa Sepsis Diagnostics Market

30. Sepsis Diagnostics Market Competitive Landscape And Company Profiles

31. Sepsis Diagnostics Market Other Major And Innovative Companies

32. Global Sepsis Diagnostics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Sepsis Diagnostics Market

34. Recent Developments In The Sepsis Diagnostics Market

35. Sepsis Diagnostics Market High Potential Countries, Segments and Strategies

36. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â